Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2E1 | P05181 | 1/20 | 0.67 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.41 |
| ▸ | GSTO1 | P78417 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL319050 | 1.00 | CYP2E1 (0.67) | CYP2E1HSD17B10ABCC1GSTO1MAPT | |
| SCHEMBL319108 | 0.93 | CYP2E1 (0.61) | CYP2E1HSD17B10ABCC1CHRM3 | |
| SCHEMBL319107 | 0.93 | CYP2E1 (0.61) | CYP2E1HSD17B10ABCC1CHRM3 | |
| SCHEMBL320239 | 0.91 | CYP2E1 (0.57) | CYP2E1HSD17B10ABCC1GSTO1MAPT | |
| SCHEMBL320238 | 0.91 | CYP2E1 (0.57) | CYP2E1HSD17B10ABCC1GSTO1MAPT | |
| SCHEMBL319087 | 0.87 | CYP2E1 (0.54) | CYP2E1HSD17B10MAPTCHRM3PTGS2 | |
| SCHEMBL319086 | 0.87 | CYP2E1 (0.54) | CYP2E1HSD17B10MAPTCHRM3PTGS2 | |
| SCHEMBL10268628 | 0.85 | CYP2E1 (0.73) | CYP2E1GSTO1MAPTEPHX2 | |
| SCHEMBL10265043 | 0.84 | CYP2E1 (0.77) | CYP2E1GSTO1CHRM3EPHX2 | |
| SCHEMBL10265780 | 0.84 | CYP2E1 (0.69) | CYP2E1GSTO1MAPTEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130190289-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-07-25 | — | — | US | disclosed |
| EP-2585447-A2 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | Vertex Pharmaceuticals Incorporated (US) | 2013-05-01 | — | — | EP | disclosed |
| WO-2012006055-A2 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130190289-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | SLC10A1, ACE, CEL | CYP2E1 1027/4885HSD17B10 862/4885ABCC1 2288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.